RAMSAY HEALTH CARE LIMITED (RHC)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

RHC

RHC - RAMSAY HEALTH CARE LIMITED

FNArena Sector : Healthcare services
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: 5.71
Index: ASX100 | ASX200 | ASX300 | ALL-ORDS

Founded in Sydney in 1964, Ramsay Health Care is the largest provider of private healthcare in Australia, with operations in the UK, France, Indonesia and Malaysia. The company specialises in surgery, rehabilitation and psychiatric care. It was first listed in 1997.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$31.46

17 Nov
2025

0.540

OPEN

$30.80

1.75%

HIGH

$31.56

425,722

LOW

$30.57

TARGET
$34.22 8.8% upside
Franking for last dividend paid out: 100%
OTHER COMPANIES IN THE SAME SECTOR
ACL . AHX . ALC . BMT . DOC . EBO . HLS . IDX . M7T . MDR . MPL . MVF . NHF . SHL .
FNARENA'S MARKET CONSENSUS FORECASTS
RHC: 1
Title FY24
Actual		 FY25
Actual		 FY26
Forecast		 FY27
Forecast
EPS (cps) xxx 3.0 134.6 xxx
DPS (cps) xxx 80.0 85.2 xxx
EPS Growth xxx - 99.2% 100.0% xxx
DPS Growth xxx 0.0% 6.5% xxx
PE Ratio xxx N/A 23.4 xxx
Dividend Yield xxx N/A 2.7% xxx
Div Pay Ratio(%) xxx 2702.7% 63.3% xxx

Dividend yield today if purchased 3 years ago: 1.28%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 2.59

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 11/03 - ex-div 40c (franking 100%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2025 FactSet UK Limited. All rights reserved
Title 202020212022202320242025
EPS Basic xxxxxxxxxxxxxxx3.0
DPS All xxxxxxxxxxxxxxx80.0
Sales/Revenue xxxxxxxxxxxxxxx17,801.7 M
Book Value Per Share xxxxxxxxxxxxxxx2,075.4
Net Operating Cash Flow xxxxxxxxxxxxxxx1,497.3 M
Net Profit Margin xxxxxxxxxxxxxxx0.13 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202020212022202320242025
Return on Capital Employed xxxxxxxxxxxxxxx0.14 %
Return on Invested Capital xxxxxxxxxxxxxxx0.15 %
Return on Assets xxxxxxxxxxxxxxx0.11 %
Return on Equity xxxxxxxxxxxxxxx0.48 %
Return on Total Capital xxxxxxxxxxxxxxx5.82 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx559.1 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202020212022202320242025
Short-Term Debt xxxxxxxxxxxxxxx686 M
Long Term Debt xxxxxxxxxxxxxxx11,434 M
Total Debt xxxxxxxxxxxxxxx12,120 M
Goodwill - Gross xxxxxxxxxxxxxxx6,264 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx784 M
Price To Book Value xxxxxxxxxxxxxxx1.77

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202020212022202320242025
Capex xxxxxxxxxxxxxxx776.6 M
Capex % of Sales xxxxxxxxxxxxxxx4.36 %
Cost of Goods Sold xxxxxxxxxxxxxxx16,075 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx729 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx111 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

-0.2

No. Of Recommendations

6
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

UBS

xx/xx/xxxx

3

xxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Citi

xx/xx/xxxx

3

xxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgan Stanley

xx/xx/xxxx

5

xxxxxxxxx xx xxxxxxxxxxx xxxx xxxxx-xxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgans

29/08/2025

3

Hold

$35.22

11.95%

Ramsay Health Care reported broadly inline FY25 results, net profit grew 1.7% and revenue by 4.6%, and only qualitative guidance for FY26 was offered.

Morgans comments higher opex weighed on low single digit admissions growth and indexation/tariff gains, with UK acute being the only region to generate solid growth.

Australia and the EU were flat and Elysium went backwards as lower occupancy and inflation pressures impacted.

There is a lot going on at Ramsay, commentary suggests, with ongoing uncertainty and headwinds in 2H25 as a multi-year transformation program is being undertaken alongside a strategic review of the EU.

Morgans highlights this as challenging earnings recovery.

In FY26, acute hospitals are seen as well positioned to benefit from NHS work, but tariffs are lower by -106bps to 2.83%. Costs continue to weigh on Elysium.

Morgans lowers its net profit after tax forecasts by -12% for FY26 and -16% for FY27. No change to Hold rating. Target moves down to $35.22 from $37.10.

FORECAST
Morgans forecasts a full year FY26 dividend of 91.00 cents and EPS of 144.00 cents.
Morgans forecasts a full year FY27 dividend of 112.00 cents and EPS of 176.00 cents.

Macquarie

xx/xx/xxxx

3

xxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Ord Minnett

xx/xx/xxxx

3

xxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

2

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Canaccord Genuity

xx/xx/xxxx

3

xxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Jarden

04/09/2025

3

Neutral

$43.64

38.72%

Jarden notes Ramsay Health Care's FY25 revenue and net profit met its forecast and the consensus. However, the result masked the EBITDA miss in the Australian business and in UK, while Ramsay Sante's underlying EBIT beat by 25%.

The broker cut revenue forecasts in Australia after factoring in weaker pricing from the Joondalup public hospital contract. UK Elysium forecast also downgraded, though partly offset by upgrades to hospital and forex tailwinds.

Sante revenue was upgraded, with further help from forex tailwinds. EPS forecast for FY26 trimmed by -5.7% and by -8.6% for FY27.

Neutral. Target lowered to $43.64 from $46.55.

FORECAST
Jarden forecasts a full year FY26 dividend of 87.10 cents and EPS of 136.00 cents.
Jarden forecasts a full year FY27 dividend of 118.70 cents and EPS of 184.50 cents.
Access Extra Coverage Research History >

RHC STOCK CHART

FNArena News on RHC

1
Rudi’s View: Amcor, Charter Hall, Challenger, Goodman, Woolworths & More

Nov 06 2025 - Rudi's View
2
Rudi’s View: Eagers Automotive, Catapult, Fineos, Pro Medicus, Woolworths & More

Oct 30 2025 - Rudi's View
3
Rudi’s View: ALS, Bega, Coles, Elders, Light & Wonder, Lovisa, Telix & More

Oct 23 2025 - Rudi's View
4
Australian Broker Call *Extra* Edition – Oct 07, 2025

Oct 07 2025 - Daily Market Reports
5
Weekly Ratings, Targets, Forecast Changes – 03-10-25

Oct 06 2025 - Weekly Reports

Latest Healthcare services News

1
Better Times Ahead For Sonic Healthcare?

Jun 20 2025 - Australia
2
The Significance Of Cosmetique’s ASX Listing

Feb 26 2025 - Small Caps
3
Building The No 3 Diagnostic Imaging Player

Jun 19 2024 - Small Caps
4
Capitol Health’s Higher Margin Outlook

Mar 13 2024 - Small Caps
5
Treasure Chest: Ramsay Health Care

Oct 26 2023 - Treasure Chest
6
Timing Seems Right For Alcidion Group

Jun 21 2023 - Small Caps
7
No Enthusiasm To Combine ACL & Healius

Mar 21 2023 - Australia
8
Dr Boreham’s Crucible: Alcidion

Dec 13 2022 - Small Caps
9
No Straight Covid-Relief For Ramsay Health Care

Nov 15 2022 - Australia
10
Dr Boreham’s Crucible: Mach7 Technologies

Nov 14 2022 - Small Caps